Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 2 May 2019 |
| Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2019 | 30 Apr 2019 |
| Novo Nordisk A/S - Share repurchase programme | 29 Apr 2019 |
| Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes | 26 Apr 2019 |
| Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A | 26 Apr 2019 |